Clinical Trial Update: Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children [Phase 1]

View source ↗

Summary

A Phase 1 trial completed and results posted evaluating infectivity, safety, and immunogenicity of two RSV vaccine candidates, RSV 6120/∆NS1 and RSV 6120/F1/G2/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV 6120/F1/G2/∆NS1
• RSV 6120/∆NS1

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: RSV Infection | Phase 1 | Status: COMPLETED | Results posted: 2026-02-13